H3K27me3 protein is a promising predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal carcinoma

Molecular Medicine

Volumn 17, Issue 11, 2011, Pages 1137-1145

  Cai, Mu Yan ^a,b   Tong, Zhu Ting ^a,c   Zhu, Wei ^a   Wen, Zhu Zhi ^b   Rao, Hui Lan ^a,b   Kong, Ling Ling ^c   Guan, Xin Yuan ^a   Kung, Hsiang Fu ^a,d   Zeng, Yi Xin ^a   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLOXURIDINE; HISTONE H3; LYSINE; PROTEIN H3K27ME3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY; RECEIVER OPERATING CHARACTERISTIC; TUMOR CLASSIFICATION; UNIVARIATE ANALYSIS; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; LYSINE; MALE; METHYLATION; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIATION TOLERANCE; ROC CURVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 82855172243     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00054     Document Type: Article

References (35)

1. Wei WI, Sham JS. (2005) Nasopharyngeal carcinoma. Lancet. 365:2041-54.
2. Chang ET, Adami HO. (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 15:1765-77.
3. Yamashita S, Kondo M, Hashimoto S. (1985) Squamous cell carcinoma of the nasopharynx. An analysis of failure patterns after radiation therapy. Acta Radiol. Oncol. 24:315-20.
4. Chua DT, et al. (2005) Long-term survival after cisplatin- based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J. Clin. Oncol. 23:1118-24.
5. Chan AT, et al. (1995) A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 33:569-77.
6. Lin JC, Chen KY, Jan JS, Hsu CY. (1996) Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 36:1127-36.
7. Al-Sarraf M, et al. (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J. Clin. Oncol. 16:1310-7.
8. Patel SG, Shah JP. (2005) TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J. Clin. 55:242-58; quiz 261-2, 264.
9. Esteller M. (2008) Epigenetics in cancer. N. Engl. J. Med. 358:1148-59.
10. Strahl BD, Allis CD. (2000) The language of covalent histone modifications. Nature. 403:41-45.
11. Lund AH, van Lohuizen M. (2004) Epigenetics and cancer. Genes. Dev. 18:2315-35.
12. Cao R, et al. (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 298:1039-43.
13. Matsukawa Y, et al. (2006) Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 97:484-91.
14. Mimori K, et al. (2005) Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur. J. Surg. Oncol. 31:376-80.
15. Sudo T, et al. (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. British J. Cancer 92:1754-8.
16. Collett K, et al. (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 12:1168-74.
17. Bachmann IM, et al. (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24:268-73.
18. Kidani K, et al. (2009) High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncology. 45:39-46.
19. Raman JD, et al. (2005) Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 11:8570-6.
20. Varambally S, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 19:624-9.
21. Yu J, et al. (2007) A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67:10657-63.
22. Wei Y, et al. (2008) Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 47:701-6.
23. Tzao C, et al. (2009) Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod. Pathol. 22:252-60.
24. He LR, et al. (2009) Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 9:461.
25. Lu TY, et al. (2009) DNA methylation and histone modification regulate silencing of OPG during tumor progression. J. Cell. Biochem. 108:315-25.
26. Min H, et al. (1994) A new staging system for nasopharyngeal carcinoma in China. Int. J. Radiat. Oncol. Biol. Phys. 30:1037-42.
27. Xie D, et al. (2003) Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int. J. Cancer 107:896-902.
28. Cai MY, et al. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci. 101:1543-9.
29. Tong ZT, et al. (2011) EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. (In press).
30. Lewis EB. (1978) A gene complex controlling segmentation in Drosophila. Nature. 276:565-70.
31. Hansen KH, et al. (2008) A model for transmission of the H3K27me3 epigenetic mark. Nat. Cell. Biol 10:1291-300.
32. Cai MY, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts patients worse prognosis. Mol. Med. 17:12-20.
33. Abbosh PH, et al. (2006) Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drugresistant phenotype in cancer cells. Cancer Res. 66:5582-91.
34. Beyersmann J, Schumacher M. (2007) Misspecified regression model for the subdistribution hazard of a competing risk. Stat. Med. 26:1649-51.
35. Cao R, Zhang Y. (2004) The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14:155-64.